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MANAGING THE CARDIOVASCULAR RISKS IN HYPERTENSION 
Introduction 
Stevo Julius, MD Ann Arbor, Mch. 
The title of this conference, “Hypertension: A View 
Beyond the Numbers,” is not just an intriguing 
phrase, it is a meaningful concept. Those of us in 
the field of hypertension today know by now that 
antihypertensive treatment prevents complications 
and decreases morbidity. The classic study pointing 
to this conclusion was the Veterans Administration 
(VA) study, which clearly showed that morbidity 
was much greater among hypertensive patients who 
were not treated than among those who were. 
Two types of morbidity are associated with high 
blood pressure. One is the pressure-related set of 
complications, that is, those related to the level of 
the blood pressure at the time the complication 
occurs. These pressure-related complications are 
cerebral hemorrhage and congestive heart failure. 
Cerebral hemorrhage results when the pressure is so 
high in the blood vessels that the vessels burst; 
congestive heart failure develops when peripheral 
resistance is so high that it offers a major impedi- 
ment to the function of the heart. 
The other set of complications arising from hyper- 
tension is related to the premature development of 
atherosclerosis. This is the area in which recent 
epidemiologic studies have uncovered some prob- 
lems. 
Certainly, hypertension contributes to the prema- 
ture development of atherosclerosis. However, treat- 
ment with antihypertensive medication has shown 
less influence on this complication of hypertension 
than on cerebral hemorrhage and congestive heart 
failure, the pressure-related events. This was one of 
the findings of the VA study. During a 4-year period, 
seven patients in the untreated group died of stroke 
and 14 had a nonfatal stroke; only one patient in the 
treated group died of stroke and only four had a 
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stroke without fatality. The use of antihypertensive 
treatment produced a major difference in this par- 
ticular cause of morbidity. On the other hand, the 
study showed no improvement with antihyperten- 
sive treatment in the morbidity from coronary heart 
disease. These rates remained unchanged. In fact, 
when one reviews the results of all the major studies, 
it appears that if there is any effect of antihyperten- 
sive treatment on reducing the morbidity and mor- 
tality from coronary heart disease, it is very small. 
This realization has been a source of disappoint- 
ment to all of us, and it raises questions of more than 
a theoretical nature. In the United States, the 
morbidity and mortality curves have followed the 
trend demonstrated in the VA study, that is, a 
dramatic decrease in the incidence of stroke but a 
much smaller decline in the incidence of cardiovas- 
cular disease, particularly coronary heart disease. 
However, in comparison with the trends in other 
countries, the decrease in coronary morbidity in the 
United States has been greatest. Some countries 
have always had a low incidence and have retained 
this profile, whereas in others the rates are increas- 
ing. Why? Surely it is not because the people are 
intrinsically different or because cultural differences 
are that strong. 
Two explanations have been proposed for the 
observation that lowering blood pressure can influ- 
ence the stroke rate but not coronary morbidity. One 
relates to the fact that in all of the present studies, 
diuretics were the first step in therapy. Diuretics 
may, by virtue of their effects on lipids, potassium, 
and glucose, produce some deleterious effects in 
areas relevant to coronary disease. 
However, this is probably not the whole explana- 
tion. More likely the explanation is that hyperten- 
sion is only one of the risk factors in coronary heart 
disease. Several lines of evidence indicate the com- 
plexity of the risk factor situation. For example, a 
combination of high cholesterol levels with high 
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blood pressure levels increases the incidence of 
morbidity. For each increment in cholesterol and 
blood pressure levels, there is a corresponding 
increase in coronary morbidity. In the highest blood 
pressure and cholesterol groups, mortality is also 
very high. However, many of these people have 
additional risk factors, such as left ventricular 
hypertrophy, glucose intolerance, and cigarette 
smoking. The curves are much flatter, and therefore 
the relationship is much weaker, in nonsmokers and 
persons without the additional risk factors. 
At one time there was some hope, which was 
partially justified, that B-blockers might improve 
the coronary risk factor picture. The study done in 
Great Britain with propranolol, a noncardioselective 
p-blocker, showed a decrease in the incidence of 
coronary events in nonsmokers with this treatment, 
although not in smokers. It is reasonable to expect 
that cardioselective &blockers may offer better car- 
dioprotection; the results of the MAPHY trial, 
which will be presented in this symposium, may 
support this theory. 
Such studies underscore the need for a host of risk 
factors that have now been linked with cardiovascu- 
lar disease to be considered in achieving truly effec- 
tive treatment for the patient with elevated blood 
pressure. The contributors to coronary morbidity 
are more complex than previously thought. Behav- 
ioral characteristics, concomitant cardiovascular 
disease, demographic factors, and age are only some 
of the factors that need to be considered. The search 
should continue for specific antihypertensive drugs 
that may help prevent primary myocardial infarc- 
tion as B-blockers have been shown to do for second- 
ary, recurrent infarction. Thus, in addition to man- 
aging blood pressure levels, the practicing physician 
will also become involved in assessing risk factors 
and differentiating between various drugs with 
increasingly selective indications. The future treat- 
ment of hypertension will indeed become a view 
beyond the numbers. 
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Although cardiovascular disease remains the leading cause of death in the United States, its 
incidence has decreased steadily during the past 20 years. This trend is largely attributable to 
improved detection and management of cardiovascular risk factors. The pioneering work of the 
Framingham Heart Study, which has followed subjects since the late 19408, has helped shed light 
on the risks conferred by factors such as advancing age, hypertension, smoking, elevated serum 
cholesterol, diabetes, left ventricular hypertrophy, and obesity. As a result of this ongoing 
investigation, clinicians have gained a better understanding of the ways in which cardiovascular 
risks can be modified so that mortality rates will hopefully continue to decline. 
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most common form of cardiovascular disease is 
coronary artery disease, which accounts for 550,000 
deaths and 1,250,OOO cardiac events each year.’ 
During the past 20 years, however, the incidence 
of mortality from cardiovascular disease has 
decreased by 33% in the United States, perhaps 
saving as many as 250,000 lives annually. At the 
same time, the incidence of death from stroke has 
